• 21 Jan 2009

Thomson Reuters has announced the availability of three Pharma Matters reports covering the time period July – September 2008.

Philadelphia, PA, London UK, January 21, 2009 – Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period July – September 2008. The quarterly Pharma Matters series covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma ®, Newport Horizon Premium TM and the Thomson Messaging Mapping System SM . 

The Ones to Watch – A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on strategic data and analysis from Thomson Pharma , the world’s leading pharmaceutical competitive intelligence solution. In the report covering Q3 2008, the top five most promising drugs launched or receiving approval were:

DRUG

DISEASE

COMPANY

Zeftera TM

Complicated skin and soft tissue infections

Basilea Pharmaceutica

Firazyr®

Hereditary angioedema

Jerini

Bridion®

Reversal of muscle relaxants

Schering-Plough

Cleviprex TM

Perioperative hypertension

The Medicines Company

Xarelto®

Venous thromboembolic events

Bayer/Ortho-McNeil Pharmaceutical

More analysis, as well as information on drugs entering clinical Phases I, II and III are available in the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.pdf

Movers and Shakers - This report covers the US generics industry using data and analysis from Newport Horizon Premium , the critical product targeting the global business development system. Analysis from the Q3 2008 report includes:

  • The pharmaceutical marketplace continued to demonstrate volatility, and the pace of patent challenges showed no sign of slackening in the third quarter of 2008.
  • During the third quarter of 2008, final approvals were issued on only 77 ‘A’-rated ANDAs, plummeting down from 142 the quarter before. First-time approvals of generic products by the FDA also dropped from 11 to 8 this quarter.
  • Seven new products (three combination products and four single active ingredient products) were subjected to paragraph IV challenges for the first time in Q3 2008, identical to the previous quarter.
  • Indian groups were in first place in terms of ANDA approvals during Q3 2008. Twelve India-based corporations received a total of 17 final ANDA approvals.
  • In the same time period, 11 US-based companies received a total of 15 approvals, putting the U.S. in second place for this quarter.
  • Mylan of the U.S. and Boehringer Ingelheim of Germany received the most final ANDA approvals (seven each).

To learn more about companies making their mark on the U.S. generics market, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008ms_q3.pdf

Who is Making the Biggest Splash? – A Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System . In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the 15 listed organizations that have made the biggest impact as the leading sources of information on medical research from July – September 2008 are:

  • Novartis
  • Bristol-Meyers Squibb
  • Eli Lilly
  • Pfizer
  • AstraZeneca

To see the complete list, as well as analysis and methodology, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008wmtbs_q3.pdf

To sign up for the Thomson Reuters Pharma Matters series of publications visit: http://scientific.thomsonreuters.com/info/matters/

About Thomson Reuters
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com .

Contacts

Susan Fitzpatrick
Manager, PR and Communications—Science
1500 Spring Garden Street
Fourth Floor
Philadelphia, PA 19130
USA
Tel: +1 215.823.1840
Email

Next Steps